Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial.
Mathias D G Van den EyndeAlfons J H M HoubenJean L J M ScheijenArmand M A LinkensPetra M NiessenNynke SimonsNordin M J HanssenYvo H A M KustersSimone J M P EussenToshio MiyataCoen D A StehouwerCasper G SchalkwijkPublished in: Diabetes, obesity & metabolism (2023)
This study shows that PM is metabolically active and reduces MGO, AGEs, sVCAM-1 and sICAM-1, but does not affect insulin sensitivity and vascular function in abdominally obese individuals. The reduction in adhesion markers is promising because these are important in the pathogenesis of endothelial damage and atherosclerosis.
Keyphrases
- double blind
- adipose tissue
- weight loss
- metabolic syndrome
- type diabetes
- clinical trial
- obese patients
- cardiovascular disease
- placebo controlled
- study protocol
- particulate matter
- oxidative stress
- bariatric surgery
- randomized controlled trial
- heavy metals
- escherichia coli
- phase iii
- cystic fibrosis
- polycyclic aromatic hydrocarbons
- open label
- water soluble
- cell migration